Moreover, a subsequent study revealed that nuclear FBP1 interacted with DNMT1 to sensitize pancreatic cancer cells to PARP inhibitors, and this effect was independent of the enzymatic activity of FBP1. The gene discussed is PARP1; the disease is pancreatic neoplasm.